Background: Cetuximab-induced hypomagnesemia has been associated with improved clinical outcomes in advanced colorectal cancer (CRC). We explored this relationship from a randomized clinical trial of cetuximab plus best supportive care (BSC) versus BSC alone in patients with pretreated advanced CRC.
introduction
The epidermal growth factor receptor (EGFR) is a tyrosine kinase transmembrane receptor that is stimulated by ligands including amphiregulin, epiregulin and transforming growth factor-α, leading to homo-or heterodimerization with ErbB family members and subsequent signaling of the Ras-Raf-MAP, PI3K and Akt pathways [1] . These pathways are important for the regulation of cell proliferation and inhibition of apoptosis and can be activated in CRC [2] . Monoclonal antibodies targeting the EGFR (e.g. cetuximab and panitumumab) have been studied in large, multicentered, randomized, controlled trials. Clinically important improvements in overall and progression-free survival have been demonstrated with cetuximab in patients with advanced CRC [3] [4] [5] both as monotherapy and in combination with chemotherapy. These benefits, however, appear to be limited to tumors without mutations of the KRAS oncogene [6, 7] .
Although the common side-effects of cetuximab (including acneiform rash, diarrhea and fatigue) were recognized in early studies, hypomagnesemia was underappreciated since these studies did not routinely collect this information [3, 8, 9] . Schrag et al. [10] first reported on a patient with cetuximabinduced supplement-resistant hypomagnesemia associated with profound fatigue, acneiform rash, parethesias and inappropriate renal wasting of Mg. Since then, the severity and incidence of EGFR monoclonal antibody-associated hypomagnesemia have been explored. A study of 98 consecutive patients treated with EGFR antibodies found that 97% of patients had decreases in serum Mg levels and 6% had grade 3/4 hypomagnesmia [11] , while a recent meta-analysis revealed that 5.6% of patients treated with cetuximab for various cancers had grade 3/4 hypomagnesemia and 36.5% had any grade of hypomagnesemia [12] .
The mechanism by which EGFR inhibition leads to hypomagnesemia has been described by Groenestege et al. [13] . Transport of Mg in the distal convoluted tubule occurs through a Mg permeable channel called TRPM6 (transient receptor potential cation channel, subfamily M, member 6) and is regulated by the epidermal growth factor. EGFR inhibition with cetuximab leads to insufficient activation of this TRPM6 channel in vitro and increased fractional excretion of Mg in patients treated with cetuximab. Similarly, Tejpar et al. [11] showed that patients treated with EGFR monoclonal antibodies had defects in renal magnesium reabsorption, using 24 h urine analysis and intravenous magnesium load testing.
What effect Mg levels have on cancer progression is an area of active research with conflicting results [14] . For example, in one study, mice fed low Mg diets had decreased primary tumor growth and low levels of neovascularization, but increased metastatic potential [15] . Recently, however, Vincenzi et al. [16] reported on the outcome of early Mg reduction in 68 patients treated with cetuximab plus irinotecan. Patients with ≥20% decrease in Mg levels from baseline had longer time to progression and overall survival (OS) compared with those patients with a lesser degree of hypomagnesemia. A subsequent larger study by the same authors in patients with KRAS wild-type tumors revealed similar results. The patients with ≥50% reduction in Mg had improved response rates, time to progression and OS [17] .
To further explore the relationship between cetuximabinduced hypomagnesemia and clinical outcomes, we correlated Mg levels with OS and toxicity using data from the NCIC CTG/AGITG CO.17 trial. This study prospectively collected Mg levels at baseline and monthly.
patients and methods patients
Five hundred and seventy-two patients with advanced CRC expressing EGFR and who had previously received, unless contraindicated, a fluoropyrimidine, irinotecan and oxaliplatin were randomly assigned to cetuximab plus best supportive care (BSC) versus BSC alone as previously described [4] . Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, adequate bone marrow, kidney, liver function and no serious concurrent illness. The patients were randomly assigned to cetuximab (initial dose 400 mg/m 2 administered over 120 min, followed by a weekly maintenance infusion of 250 mg/m 2 administered over 60 min) plus BSC (measures designed to provide palliation of symptoms and improve the quality of life) (N = 287) versus BSC alone (N = 285). The treatment was continued until death, unacceptable toxicity, tumor progression, worsening symptoms of cancer or patient request. The primary analysis has been reported, demonstrating a significant prolongation of overall and progression-free survival in favor of cetuximab plus BSC [4] . Further, a post-hoc analysis of the KRAS mutation status revealed a significant benefit of cetuximab in wild-type KRAS tumors, while those harboring a mutated KRAS did not benefit [6, 18] .
hypomagnesemia
In the CO.17 trial, serum Mg levels were assessed at baseline, then every 4 weeks while on study in both the arms of the study. Hypomagnesemia was defined using the National Cancer Institute Common Toxicity Criteria toxicity scale, version 2.0 and by percent reduction from baseline levels. To avoid bias related to the influence of time on therapy as a function of hypomagnesemia, a landmark analysis was conducted, where patients who died within 28 days were excluded. In addition, patients without a Mg measurement at week 4, those without a baseline magnesium measurement (for percent reduction analysis) and those without tissue available for KRAS testing (for KRAS subgroup analysis) were excluded ( Figure 1 ).
statistical analysis
OS was defined as the time from randomization until death from any cause and analyzed in an intent-to-treat fashion. Progression-free survival was defined as the time from randomization until the first objective observation of disease progression or death from any cause.
A chi-square test was used to assess the association between hypomagnesemia (grade 0 versus ≥1 and percent reduction ≥20% versus <20%), gender, age, ECOG PS, rash and treatment allocation. The predictive effect of hypomagnesemia was assessed by a log-rank test in univariate analysis and Cox regression models in multivariate analysis, adjusting for the following potential prognostic variables: ECOG PS (0-1 versus 2), gender (male versus female), age (≥65 versus <65 years), baseline lactate dehydrogenase (> upper limit of normal (ULN) or ≤ULN), baseline hemoglobin levels (grade ≥1 versus 0), baseline alkaline phosphatase (>ULN versus ≤ULN), number of disease sites (>2 versus ≤2), number of previous chemotherapy drug classes (>2 versus ≤2), primary tumor site (rectum versus colon) and liver metastases ( present versus absent). . This corresponded to a median percentage (%) Mg reduction at day 28 of 10% (−42.4% to 63.0%) for patients on cetuximab and 0% (−21.1% to 25%) on the BSC arm (P < 0.0001) ( Table 1 ). Due to the lack of change in Mg in the BSC arm, analysis of hypomagnesemia as a prognostic or predictive biomarker in this group was not possible and the remainder of the results pertain to the cetuximab-treated arm only. Among the cetuximab-treated patients, 163 (75%) had grade 0 and 53 (25%) had grade ≥1 hypomagnesemia on day 28. Using percent reduction of Mg, 172 (84%) patients had <20% reduction, while 31 (16%) had ≥20% Mg reduction on day 28. The only baseline characteristic that predicted for the development of hypomagnesemia as assessed by grade ≥1 and ≥20% reduction was ECOG PS 2 (P = 0.006 and P = 0.008, respectively) ( Table 2) .
Among cetuximab-treated patients with KRAS wild-type tumors, 73 (81%) patients had grade 0, while 17 (19%) had grade ≥1 hypomagnesemia on day 28. Seventy-five (89%) of these patients had <20% reduction, while 9 (11%) had ≥20% reduction of magnesium on day 28. Among KRAS wild-type status patients, no baseline characteristic predicted for the development of hypomagnesemia, as defined by grade or percent reduction of Mg (data not shown).
Among cetuximab-treated patients with KRAS-mutant tumors, 45 (73%) patients had grade 0, while 17 (27%) had grade ≥1 hypomagnesemia on day 28. Forty-nine (83%) of these patients had <20% reduction, while 10 (17%) had ≥20% reduction of magnesium on day 28. Among patients with KRAS-mutant status tumors, the only baseline characteristic that predicted for the development of hypomagnesemia on day 28 was ECOG PS 2, which was more often associated with a ≥20% magnesium reduction (P = 0.001) (data not shown).
hypomagnesemia and overall survival
In the landmark-type analysis of the association between hypomagnesemia at day 28 and OS in cetuximab-treated patients, OS was worse among patients who experienced greater levels of hypomagnesemia. The median OS was 3.7 versus 8.0 months for grade ≥1 versus 0, respectively [adjusted HR 1.60 (95% CI 1.10-2.31), P = 0.01] (Figure 2A) . Similarly, the median OS was 3.8 versus 7.6 months for patients with ≥20% versus <20% reduction in magnesium, respectively [adjusted HR 2.01 (95% CI 1.28-3.16), P = 0.003] ( Figure 2B ).
Among patients with KRAS wild-type tumors, the results were similar. Higher grade of hypomagnesemia associated with worse OS [median 4.4 versus 9.9 months for grade ≥1 versus 0, respectively; adjusted HR 2.22 (95% CI 1.10-4.51), P = 0.03] ( Figure 3A ) and trending towards worse OS based on percent reduction [6.5 versus 9.8 months for patients with ≥20% versus <20% Mg reduction, respectively; adjusted HR 2.30 (95% CI 0.96-5.51), P = 0.06] ( Figure 3B) .
Only a trend toward worse OS with higher grade of hypomagnesemia was observed among patients with KRASmutant status tumors. The median OS was 3.5 versus 5. day 28 hypomagnesemia and other coincident toxic effects
Hypomagnesemia at day 28 was associated with only a few other toxic effects over the course of the patient's time on trial. The incidence of anorexia of any grade or cause was significantly higher in patients with grade ≥1 compared with grade 0 hypomagnesemia at day 28 (81% versus 63%, P = 0.02). The findings were similar among KRAS wild-type status patients (88% versus 62%, P = 0.05). Any cause and grade dyspnea at any time on trial was significantly higher in those with ≥20% compared with <20% reduction in Mg levels from baseline (68% versus 45%, P = 0.02) for all cetuximab-treated patients (Table 3) .
dose intensity
Among cetuximab-treated patients, the proportion of patients receiving ≥90% of planned dose intensity did not differ substantially by percent reduction of Mg from baseline, or grade of hypomagnesemia, aside from a higher dose intensity in the subgroup of patients with KRAS wild-type tumors and a <20% reduction in Mg from baseline (supplementary table S1 , available at Annals of Oncology online).
grade of rash, hypomagnesemia and overall survival
The grade of rash was not significantly associated with grade of hypomagnesemia or percent reduction of Mg (supplementary  table S2 , available at Annals of Oncology online). Inclusion of grade of rash (0-1 versus 2+) at 28 days in multivariate analysis revealed that hypomagnesemia by grade retained significance for OS, while grade of rash lost significance ( Figure 5 ).
discussion
The discovery that the KRAS mutation status was a predictive biomarker of benefit from EGFR monoclonal antibody therapy was a major step towards personalizing therapy in advanced CRC. In an attempt to further characterize patients who derive benefit from cetuximab, we assessed the predictive capacity of changes in Mg levels in the NCIC/AGITG CO.17 clinical trial. In contrast to prior reports [16, 17] , we have shown that higher grade of hypomagnesemia and greater percent reduction in Mg at day 28 predict worse survival in patients treated with cetuximab. Moreover, survival was worse in patients with grade ≥1 hypomagnesemia for both KRAS wild-type and mutant populations and trended towards statistically significant worse survival by percent reduction of Mg in these groups. Interestingly, hypomagnesemia remained significantly associated with OS even with the inclusion of grade of rash (which became nonsignificant) in our Cox model. Grade of rash was also not significantly associated with grade of The biologic relationship between Mg and cancer progression is unclear, and as with most investigations into cancer biology, likely involves complex interactions between multiple intracellular pathways, the extracellular matrix and possibly the immune system [14] . Adding to the complexity of Mg homeostasis and cancer progression, our results contradict those of Vincenzi et al. [16, 17] . This may be explained by the differences in baseline Mg levels, degree of hypomagnesemia and therapies used. In our study, the median Mg levels at baseline was 0.83 mmol/l compared with 2.12 mg/dl (∼0.87 mmol/l) in their initial cohort of 68 patients [16] and was not reported in their subsequent analysis of 143 patients with KRAS wild-type tumors [17] . Importantly, grade 1 or higher hypomagnesemia developed in 54 patients (24.7%) in our study compared with only 3 patients (4.4%) in Vincenzi's initial cohort (no patient developed > grade 1 hypomagnesemia). By comparing the grades of hypomagnesemia in KRAS wild-type patients, we found that 17 of our patients (18.9%) developed grade ≥1 hypomagnesemia compared with 9 patients (6%) by Vincenzi et al. [17] , even though 55% had >50% Mg reduction from baseline. This observation is consistent with previous findings that patients with a higher baseline magnesium level had steeper slopes in Mg reduction [11] . Although irinotecan added to cetuximab has been associated with higher rates of hypomagnesemia compared with irinotecan alone [19] , this is unlikely to explain the different results between studies since the baseline levels of Mg were lower in our study and Mg reached lower levels compared with the cohorts of Vincenzi et al. In addition, in their original cohort, a cut off of >20% reduction was associated with survival, while this did not hold up in the larger, subsequent analysis where a >50% reduction was associated with improved clinical outcomes. Further, Vincenzi's studies treated patients with cetuximab and irinotecan and therefore, our study of cetuximab monotherapy gives a clearer indication of the true impact of cetuximab on Mg levels. Another important difference is our use of a landmark analysis which excluded patients who died within 28 days of randomization. If included, these patients, who would be unlikely to develop hypomagnesemia due to insufficient time on therapy, may support the conclusion that hypomagnesemia is associated with improved survival. One could also hypothesize that hypomagnesemia is a surrogate of physiological decline as there was association of higher levels of hypomagnesemia in ECOG PS 2 patients. The adjustment for PS in our OS analyses and the minimal changes of Mg in the BSC arm argue against this as an explanation for our findings.
In unselected populations, higher grade of rash has been associated with improved clinical outcomes in patients treated with cetuximab [3, 4] and panitumumab [5] . This association was maintained when the KRAS mutation status is taken into account as in the CRYSTAL trial [20] and a third line study of panitumumab versus best supportive care [21] . The etiology of rash is poorly understood but is thought to involve the inhibition of EGFR in the basal layer of the epidermis and hair follicles [22] . Very little is known about the possible pharmacogenomic interactions of the EGFR pathways in the skin and tumor, but similar genetic makeup in these tissues may be at the core of this relationship. A similar explanation could be suggested for the relationship between hypomagnesemia and clinical benefit to EGFR inhibitors, except that our study shows the inverse relationship. It could be hypothesized that a moderate level of hypomagnesemia may be associated with an antitumor effect, while more severe hypomagnesemia could result in an opposite effect with progression of tumors. Interestingly, our study showed that hypomagnesemia was a more important factor for predicting outcome compared with rash (and causes opposite effects on clinical outcomes). More research is required to explore the possible pharmacodynamic/pharmacogenetic associations between EGFR inhibitors and magnesium homeostasis, as the underlying mechanism may be different from that of rash. Our study is the largest assessment of the cetuximabinduced hypomagnesemia on clinical outcomes in advanced CRC and is the first to show a deleterious effect of hypomagnesemia among patients with KRAS-mutated tumors. Further, Mg levels were analyzed locally at each center, making assessment of this possible biomarker available to clinicians. Despite our findings, several questions remain unanswered, such as what is the effect of hypomagnesemia on tumor growth in untreated patients with advanced CRC. The prognostic role of hypomagnesmia could not be assessed in our trial as only 14 patients in the best supportive care arm of our study had grade ≥1 hypomagnesemia and only 1 had ≥20% reduction in Mg from baseline. Is there an underlying biologic link between hypomagnesemia due to EGFR inhibitors and CRC progression? Recently it has been shown that a homolog of the TRPM6 channel, transient receptor potential melastatin 7 (TRPM7) [23] may have a role not only in Mg homeostasis, but also in the development of CRC [24] . Using data from the Tennessee Colorectal Polyp Study, Dai et al. showed that a polymorphism (Thr1482Ile) in the TRPM7 gene was associated with an increased risk of polyps and suggests that this gene may play a role in colon cancer pathogenesis. Curiously, we found that grade ≥1 hypomagnesemia at day 28 was shown to be a negative predictor of survival in the cetuximab-treated KRAS-mutant population, again suggesting a possible unifying link between EGFR inhibitors, hypomagnesemia and tumor progression. Can Mg supplementation reverse the deleterious effects of EGFR inhibitor hypomagnesemia? Since the NCIC CTG CO.17 trial was designed before knowledge of cetuximabinduced hypomagnesemia, supplementation of Mg was not mandated in the protocol. Consequently, it is unlikely that patients received Mg supplementation between day 0 and 28, thus limiting any conclusions on the effect and form of Mg supplementation.
In conclusion, we have shown for the first time that hypomagnesemia at day 28 is associated with worse survival in patients treated with cetuximab, and that this biomarker has a greater predictive capacity than grade of rash. Further studies are needed to validate this finding and to understand whether there is a unifying biological link between hypomagnesemia, the EGFR pathway and colorectal cancer progression. disclosure
